A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Clinical trial NCT07678307 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07678307
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

T-Cell Acute Lymphoblastic Leukemia T-Lymphoblastic Lymphoma Relapsed/Refractory Hematologic Malignancies

Start date: 2026-06-30
Primary completion: 2027-12-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.